INTERNATIONAL PATENT: INSILICO MEDICINE IP LIMITED, EXELIXIS, INC. FILES APPLICATION FOR "HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER"

GENEVA, Nov. 5 -- INSILICO MEDICINE IP LIMITED (26th Floor, Three Exchange Square, 8 Connaught Place CentralHong Kong, Hong Kong), EXELIXIS, INC. (1851 Harbor Bay ParkwayAlameda, California 94502) filed a patent application (PCT/US2025/026424) for "HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER" on Apr 25, 2025. With publication no. WO/2025/227060, the details related to the patent application was published on Oct 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ZHANG, Man (Suite 901, Tower C, Changt...